444 related articles for article (PubMed ID: 26698255)
1. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
2. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
[TBL] [Abstract][Full Text] [Related]
3. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
[TBL] [Abstract][Full Text] [Related]
5. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
[TBL] [Abstract][Full Text] [Related]
6. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
[TBL] [Abstract][Full Text] [Related]
7. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
[TBL] [Abstract][Full Text] [Related]
8. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
[TBL] [Abstract][Full Text] [Related]
9. Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.
Bonnet E; Ruidavets JB; Genoux A; Mabile L; Busato F; Obadia M; Prévoteau F; Marchou B; Massip P; Marion-Latard F; Delpierre C; Bernard J; Perret B
BMC Infect Dis; 2013 Jun; 13():293. PubMed ID: 23809140
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
Mora S; Sala N; Bricalli D; Zuin G; Chiumello G; Viganò A
AIDS; 2001 Sep; 15(14):1823-9. PubMed ID: 11579244
[TBL] [Abstract][Full Text] [Related]
11. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
[TBL] [Abstract][Full Text] [Related]
13. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
[TBL] [Abstract][Full Text] [Related]
16. Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients.
Marques de Menezes EG; de Paula FJ; Machado AA; de Assis Pereira F; Barbosa Júnior F; Navarro AM
Bone; 2013 Nov; 57(1):62-7. PubMed ID: 23891908
[TBL] [Abstract][Full Text] [Related]
17. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
18. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
[TBL] [Abstract][Full Text] [Related]
19. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
Carr A; Miller J; Eisman JA; Cooper DA
AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.
Aydın OA; Karaosmanoglu HK; Karahasanoglu R; Tahmaz M; Nazlıcan O
Braz J Infect Dis; 2013; 17(6):707-11. PubMed ID: 24076108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
